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Edited by Ivan SadowskiAbstract The interferon inducible transmembrane (IFITM)
proteins mediate several cellular processes such as homotypic cell
adhesion functions of interferons (IFNs) and cellular anti-prolif-
erative activities. We show that the BAF complex-mediated
induction of IFITM3 is dependent on binding of the transcrip-
tional enhancer factor 1 (TEF-1/TEAD1) to the M-CAT like
elements of its promoter. TEF-1 knock-down reduced the BAF
complex-mediated activation of IFITM3 promoter. In the ab-
sence of the BAF complex, TEF-1 is repressive to IFITM3
expression. The regulation of IFITM3 by TEF-1 demonstrates
that TEF-1 dependent regulation is more widespread than its
previously established role in the expression of muscle speciﬁc
genes.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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TEAD11. Introduction
Interferons (IFNs) play critical roles in tumor surveillance
by controlling apoptosis and through cellular anti-proliferative
and diﬀerentiating activities. They also play major roles in cel-
lular defense against viral and parasitic infection [1,2]. The
expression of several interferon inducible genes require the
chromatin remodeling SWI/SNF-like BAF complexes for their
basal as well as the IFN inducible expression [3–6]. Among
these are the interferon inducible transmembrane protein
(IFITM) family genes, which comprise of IFITM1 (9-27),
IFITM2 (1-8D) and IFITM3 (1-8U) [7,8]. These genes have
been implicated in several cellular processes such as homotypic
cell adhesion functions of IFN and cellular anti-proliferative
activities [7,9,10]. The expression level of IFITM genes have
also been found to be up-regulated in a number of cancer cells
[1,10].
We previously found that the BAF complex is constitutively
associated with the promoters of the IFITM genes and main-
tains an open chromatin structure at the promoter for rapid
induction by IFNs or viral infection [3]. We had also shown
that the BAF complex-mediated induction of the IFITM3 is
dependent on two critical DNA elements in its promoter [5].
The ﬁrst element located between the positions 152 and
138, contains an Spl binding motif. Spl recruited BAF com-*Corresponding author. Fax: +1 301 480 0961.
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doi:10.1016/j.febslet.2007.12.033plex to the promoter and a mutation in this site reduced BAF
complex-mediated activation signiﬁcantly. The second element
was identiﬁed upstream of the Spl binding motif, between the
positions 173 and 152. Deletion of this region resulted in a
signiﬁcant reduction in the BAF complex-mediated activation
as well. Though the sequence analysis of this region did not
reveal any consensus protein-binding motifs [5], a sequence,
5 0-AGGAATTTGT-3 0, resembling an M-CAT motif was iden-
tiﬁed. In this study, we present evidence that the second critical
element in the IFITM3 promoter is bound by the transcrip-
tional enhancer factor 1 (TEF-1/TEAD1). TEF-1 regulates
the BRG1-dependent activation and IFN-induction of the
IFITM3 gene.2. Materials and methods
2.1. Constructs and antibodies
pREP4-Luc, pREP7-BRGl and pREP4-puro were described earlier
[3,6]. pREP4-TM3-Luc was constructed as reported earlier, by PCR
amplifying the IFITM3 promoter from position 238 to 25 [5]. Point
mutations of the IFITM3 promoter were performed using the Quick-
Change kit (Stratagene). TEF-1 antibodies were obtained from BD
transduction laboratories (610923).2.2. Cell culture, transfection and luciferase assay
SW-13 and Hela cells were maintained in Dulbeccos modiﬁed
Eagles medium supplemented with 10% fetal bovine serum and
1 mM glutamine. For reporter assays, the reporter constructs were
transfected into SW-13 or HeLa cells and luciferase activity was mea-
sured 72 h after transfection using the dual luciferase assay kit (Prome-
ga). Transfections were carried out using superfect transfection reagent
(Qiagen).2.3. Electrophoretic mobility shift assay (EMSA)
For EMSA, the nuclear extracts from SW-13 and HeLa cells or the
in vitro translated TEF-1 were used. Detailed nuclear extracts isolation
and EMSA procedures are provided in the supplementary information.2.4. DNA aﬃnity protein puriﬁcation and mass spectrometry
For DNA aﬃnity puriﬁcation, biotinylated oligonucleotides
containing the 7-bp protein-binding site were concatamerized using
the self primed PCR technique [11,12]. Complete details of the
DNA aﬃnity protein puriﬁcation are provided in the supplementary
information. MALDI-TOF mass spectrometry was carried out
at the Lerner Research Institute, Mass Spectrometry Laboratory
for Protein Sequencing, the Cleveland Clinic Foundation, Cleveland,
OH.
2.5. RNA interference, RNA isolation, cDNA synthesis and quantitative
PCR
TEF-1 siRNAs were obtained from Qiagen. Total RNAs were iso-
lated from HeLa or SW-13 cells as described earlier [6]. cDNA wasEuropean Biochemical Societies.
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(Invitrogen). TaqMan probes and universal RT-PCR master mix were
obtained from Applied Biosystems Inc.
2.6. In vitro translation
HeLa cell mRNAs were used to synthesize the cDNA encoding
TEF-1. The cDNA was cloned into the vector, pBluescript KS (Strat-
agene). TNT Quick Coupled Transcription/Translation system was
used for in vitro translation (Promega).3. Results
3.1. Identiﬁcation of the sites essential for IFITM3 promoter
activation
SW-13 cells do not express detectible levels of either BRGl
or hBRM, the essential ATPase subunits of the BAF com-
plexes. Reconstitution of active BAF complex by the transient
expression of BRGl activates a number of genes including the
IFN-inducible IFITM3 [6]. We previously found that a 213 bp
promoter fragment of IFITM3 contains sequences responsive
to BRGl activation in SW-13 cells [5]. Though the Spl binding
site between 144 and 139 plays a critical role, the region be-
tween 173 and 152 also contributes signiﬁcantly to the
BRGl-mediated activation of the IFITM3 promoter [5], sug-
gesting that more elements may mediate the BRGl activation.
To identify the BRGl response sequences between the posi-
tions 173 and 152 of the IFITM3 promoter, we generatedA
B
Fig. 1. Identiﬁcation of the sites critical for the BAF complex dependent r
positions 175 and 138 of the IFITM3 promoter in the luciferase reporter
important for the IFITM3 promoter activation is shown in bold. Mut A to
binding site mutant. Right panel: luciferase activities of the corresponding co
this ﬁgure C and Fig. 3A–C. WT: wild-type probe; M: mutant probe, mutated
excess of the wild-type or mutant competitors were used. WT: wild-type com
Arrow – non-speciﬁc band.luciferase constructs containing the sequences from 238 to
25 in pREP4 episomal vector, which forms a regular chroma-
tin structure. Mutants were constructed with mutations span-
ning the promoter region between 175 and 138. Activities
of the constructs were analyzed by transient transfection as-
says (Fig. 1A). The wild-type promoter construct showed an
activation of over 10-fold when BRGl was transiently transfec-
ted into the cells. Mutation C resulted in the most signiﬁcant
decrease in promoter activity, whereas the mutations A and
B modestly reduced the promoter activity (Fig. 1A). Mutation
E, which overlaps the mutation C also showed a modest reduc-
tion in the promoter activity. Thus, the mutations C and E to-
gether are a 7-bp region that is important in mediating the
BRGl activity.
To analyze the protein–DNA interactions in this region we
carried out electrophoretic mobility shift assays (EMSA) using
a 21-bp [c32P]ATP labeled oligonucleotide probe spanning
the positions from 162 to 142 (Fig. 1B). When incubated
with the nuclear extracts of SW-13 cells, retardation in the
migration of the wild-type probe due to the formation of a
protein/DNA complex was observed (Fig. 1C, lane 1). Compe-
tition with a 100-fold excess of the unlabelled probe diminished
the signal intensity of the complex (Fig. 1C, lane 2). Further-
more, an excess of the unlabelled mutant probe with mutations
in the 7-bp sequence (Fig. 1B, highlighted in bold), did not
compete with the complex (Fig. 1C, lane 3), showing that the
protein–DNA interaction was speciﬁc.C
egulation of IFITM3 promoter. (A) Left panel: sequence between the
constructs (pREP4-TM3-Luc). WT: wild-type promoter. The 7-bp site
Mut E: promoter mutants, mutated sites are indicated; Spl Mut: Spl
nstructs. (B) Sequence of the oligonucleotide probes used for EMSA in
site shown in bold. (C) EMSA with SW-13 nuclear extracts. A 100-fold
petitor (lane 2); M: mutant competitor (lane 3); lane 1: no competitor.
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promoter
To identify the proteins that bind to the probe, we used
DNA aﬃnity chromatography. In this procedure, biotinylated
oligonucleotides containing the 7-bp protein-binding site
(Fig. 1B, WT) were concatamerized by PCR ampliﬁcation
[11,12]. The PCR products were bound to streptavidin coated
magnetic beads and were incubated with SW-13 nuclear ex-
tracts. The bound factors were resolved on an SDS–PAGE
gel and stained with silver nitrate (Fig. 2A, WT). In parallel,
control puriﬁcation was carried out with mutant oligonucleo-
tides (Fig. 1B, M). A comparison of the protein bands from
the two samples revealed a 50-kDa band in the wild-type elu-
ate, which was absent in the mutant eluate (Fig. 2A, compare
lanes WT and M). The protein band was excised from the gel
and analyzed by matrix-assisted laser desorption time-of-ﬂight
(MALDI-TOF) mass spectrometry. Six peptides were identi-
ﬁed from this sample, which were identical to the sequence
of the protein, transcriptional enhancer factor 1 (TEF-1)
(Fig. 2B). TEF-1 is a member of the eukaryotic TEA/ATTS
family of transcription factors, which contains the highly con-
served DNA binding domain that recognize the canonical M-
CAT sequence motif, 5 0-AGGAATG-3 0 [13,14].
To investigate whether the probe shift in the EMSA assays
(Fig. 1C) were caused by the binding of TEF-1, we carried
out EMSA supershift assays using anti TEF-1 antibodies.
TEF-1 antibodies supershifted the protein/DNA complex
formed with both SW-13 (Fig. 3A, lane 4) and HeLa nuclear
extracts (Fig. 3B, lane 4). Addition of pre-immune serum did
not result in any supershifted complexes (Fig. 3A and B, lanes
3). We then used the in vitro translated TEF-1 to conﬁrm its
binding to the probe. As shown in Fig. 3C, the in vitro trans-
lated TEF-1 formed a complex with the probe, with migration
similar to that observed with the endogenous TEF-1 in SW-13
(Figs. 1C and 3A) and HeLa nuclear extracts (Fig. 3B). While
100-fold excess of wild-type unlabelled probe competed with
the complex formation, the mutant probe did not (Fig. 3C,
compare lanes 2 and 3). In addition, the in vitro translated
TEF-1/probe complex was supershifted when incubated with
TEF-1 antibodies (Fig. 3C, lane 5). Thus, the properties of
the in vitro translated TEF-1 were similar to that of the endo-A B
Fig. 2. Puriﬁcation and identiﬁcation of the protein binding to the 7-bp re
nuclear extracts by DNA aﬃnity chromatography using the wild-type (Fig. 1
and stained with silver nitrate. The 50-kDa band (arrow) was excised from t
peptides that were identiﬁed by MALDI-TOF MS and their positions in thegenous protein, conﬁrming that the protein bound to the probe
was indeed TEF-1.
The IFITM3 promoter contains another sequence, between
the positions 170 and 164 (5 0-AGTAATT-3 0), that resem-
bles the M-CAT sequence. Mutation of this sequence also
caused a modest decrease in BRGl-induced activation
(Fig. 1A, Mut B). We used EMSA to examine whether TEF-
1 can bind to this sequence. For this, we used a 36-bp probe
(Fig. 3D, probe WT1), encompassing both the 170 5 0-
AGTAATT-3 0 164 region (Fig. 3D, site B, in bold) and the
identiﬁed TEF-1 binding site (Fig. 3D, site A, in bold) in the
IFITM3 promoter. When incubated with SW-13 nuclear ex-
tracts, the probe formed a protein/DNA complex, which was
supershifted by TEF-1 antibodies (Fig. 3E, lanes 1 and 2).
Mutation in site B (Fig. 3D, probe M2) did not alter the gel
mobility shift or the supershift with TEF-1 antibodies
(Fig. 3E, lanes 3 and 4). There was no signiﬁcant variation
in the signal intensity of the shifted complexes formed with
the wild-type and mutant probe, M2 (Fig. 3E, compare lanes
1, 2 with 3, 4) showing that the TEF-1 binding is largely unaf-
fected. When site A in the probe was mutated (Fig. 3D, probe
Ml) the protein/DNA complex signal intensity was greatly re-
duced (Fig. 3E, lanes 5 and 6), showing that TEF-1 bound the
probe much less eﬃciently. Interestingly, the migration pattern
in the EMSA and EMSA supershift assays was similar to that
of the wild-type probe showing that indeed TEF-1 has a sec-
ondary binding site between the positions 170 and 164 of
the IFITM3 promoter. Thus, the reduction in the BRG1 med-
iated activation in the IFITM3 promoter mutant B (Fig. 1A,
Mut B) could be attributed to the loss of a TEF-1 binding site.
To conﬁrm that the bands observed in Fig. 3E, lanes 5 and 6,
were due to the binding of TEF-1 to site B and not due to some
residual binding to the mutated site A, we carried out EMSA
with a shorter probe which lacked site A (Fig. 3D, probe
WT2). The migration of the wild-type probe was retarded by
the in vitro translated TEF-1 and the complex was supershifted
by TEF-1 antibodies (Fig. 3E, lanes 7 and 8). When site B in
the probe was mutated (Fig. 3D, M3), no retardation of the
probe migration was seen (Fig. 3E, lanes 9 and 10), showing
clearly that the TEF-1 bound to a secondary site in the
IFITM3 promoter, though much less eﬃciently.gion of the IFITM3 promoter. (A) Proteins puriﬁed from the SW-13
B, WT) and mutant probes (Fig. 1B, M) were resolved by SDS–PAGE




Fig. 3. TEF-1 binds to the IFITM3 promoter. (A) EMSA of the wild-type probe (Fig. 1B) with SW-13 nuclear extracts. A protein/DNA complex was
formed (lane 1) which was competed by a 100-fold excess of the unlabeled wild-type probe (WT). TEF-1 antibody super-shifted the complex (lane 4),
while the pre-immune serum did not (lane 3). The shifted and supershifted bands are indicated by arrows. (B) EMSA was performed as above, with
HeLa nuclear extracts. (C) EMSA was performed as above, with in vitro translated TEF-1. M: 100-fold excess of the mutant probe (Fig. 1B, M). (D)
WT1, Ml and M2: probes used in the EMSA shown in E, lanes 1–6 (WT1: lanes 1 and 2; Ml: lanes 5 and 6; M2: lanes 3 and 4). Sites A and B: primary
and secondary TEF-1 binding sites, respectively, in the wild-type probe (WT). Ml and M2: site A and site B mutant probes, respectively. Mutated
sites are in bold. WT2 and M3: probes used in the EMSA shown in E, lanes 7–10 (WT2: lanes 7 and 8; M3: lanes 9 and 10). WT2: wild-type probe,
M3: mutant probe. Mutated sites are in bold. (E) EMSA with the SW-13 nuclear extracts and in vitro translated TEF-1.The protein/DNA complex
formed between the SW-13 nuclear extracts and the wild-type probe (WT1, lane 1) is supershifted by TEF-1 antibodies (lane 2). A protein/DNA
complex is formed with the site B mutant probe (M2, lane 3) and is supershifted by the TEF-1 antibodies (lane 4). The complex formation is
signiﬁcantly reduced when the site A mutant (Ml) probe was used. A very faint complex formation is observed (lane 5, arrow) that is supershifted by
TEF-1 antibodies (lane 6, arrow). The protein/DNA complex formed between the in vitro translated TEF-1 and the wild-type probe (WT2, lane 7) is
supershifted by TEF-1 antibodies (lane 8). The mutant probe (M3, lanes 9 and 10) did not form a speciﬁc complex. The non-speciﬁc bands in lanes 9
and 10 are marked with arrows.
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IFITM3 promoter in vivo, using chromatin immunoprecipita-
tion (ChIP) assays. Unfortunately, we could not detect enrich-
ment with the TEF-1 antibodies compared to pre-immune
controls (data not shown), which can be explained by inacces-
sible epitopes or antibodies not being suitable for ChIP analy-
sis. Therefore, we used the following methods to conﬁrm the
involvement of TEF-1 in IFITM3 regulation.
3.3. IFITM3 promoter activity is dependent on TEF-1
In order to determine whether TEF-1 is involved in the reg-
ulation of IFITM3, we knocked-down TEF-1 in cultured cells.
As shown in Fig. 4A, knock-down of TEF-1 in SW-13 cells by
transfection with siRNAs targeting TEF-1 mRNA resulted in
its reduction by over 70% and a similar reduction in the pro-
tein levels was also observed (Fig. 4B). Neither BRGl expres-sion nor IFN-a treatment aﬀected the TEF-1 expression level
(Fig. 4A). The basal expression of IFITM3 was low in SW-
13 cells (Fig. 4C). Induction with IFN-a resulted in a slight in-
crease in the expression. Transient transfection of BRGl and
thereby reconstitution of the active BAF complex resulted in
a signiﬁcant increase in the basal and the IFN-a induced
IFITM3 expression levels (Fig. 4C). When TEF-1 levels in
the cells were reduced by siTEF-1, a two-fold decrease of the
BRGl-mediated induction of the basal IFITM3 expression
was observed (Fig. 4C). A corresponding decrease in the
IFN-a induced expression level also was also observed. Inter-
estingly, the basal and the IFN-a induced levels of IFITM3
expression were higher in TEF-1 knock-down SW-13 cells
in the absence of the active BAF complex, when com-
pared to the cells without TEF-1 knock-down (Fig. 4C).
This suggests a repression activity caused or mediated by
AC D
B
Fig. 4. TEF-1 knock-down results in the reduction of IFITM3 promoter activity and expression levels. (A) SW-13 cells were transfected with si TEF-
1 RNA oligonucleotides or the control RNA oligonucleotides and co-transfected with either pREP7-BRGl-hygromycin or pREP7-hygromycin
control vector. Total RNAs were isolated from the cells selected with hygromycin for 48 h and TEF-1 mRNA levels were determined using
quantitative real-time PCR. The cells were induced with 1000 u/ml a-interferon (IFN-a) for 12 h. (B) Western blot showing the TEF-1 levels in SW-
13 cells transfected with siTEF-1 RNA oligonucleotides or the control RNA oligonucleotides and co-transfected with pREP7-hygromycin. Protein
was isolated from the cells selected with hygromycin for 48 h. b-actin was used as control (C) IFITM3 mRNA levels in SW-13 cells. Conditions same
as in A. (D) IFITM3 promoter activity in the wild-type and TEF-1 knock-down HeLa cells. pREP4-TM3-Luc was co-transfected into HeLa cells
with siTEF-1 RNA oligonucleotides or the control RNA oligonucleotides. The cells were induced with 1000 u/ml IFN-a for 12 h. Luciferase activity
was measured 48 h after transfection.
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moter.
TEF-1 regulation of IFITM3 promoter was also tested in
HeLa cells, which has an active BAF complex. As shown in
Fig. 4D, IFN-a treatment induced the promoter activity signif-
icantly. Transfection of the siTEF-1 into HeLa cells, which
caused 70% reduction in the TEF-1 expression (data not
shown), resulted in a signiﬁcant decrease in both the basal
and IFN-a induced promoter activity (Fig. 4D).4. Discussion
TEF-1 belongs to a family of four transcription factors that
also include TEF-3, TEF-4 and TEF-5. They contain the
highly conserved N-terminal TEA-DNA binding domain
(TEAD) [13–16] recognizing the canonical M-CAT motif in
several muscle-speciﬁc gene promoters [17–19]. While TEF-1
is known to regulate several M-CAT dependent promoters
that are muscle speciﬁc, TEF-1 mRNA has been detected in
several other tissues, suggesting that the M-CAT binding activ-
ity could be involved in the regulation of non-muscle speciﬁc
genes as well [20]. In this study, we have found that TEF-1 reg-
ulates the interferon-inducible IFITM3 gene in non-muscle
cells.EMS A assays showed that the TEF-1 protein binds specif-
ically to the 5 0-AGGAATT-3 0 sequences between the positions
155 and 149 in the IFITM3 promoter. This is a one base
pair variation from the canonical M-CAT motif, 5 0-AG-
GAATG-3 0. Mutation in the TEF-1 binding site resulted in
signiﬁcant reduction in the promoter activity (Fig. 1A).
Knock-down of the TEF-1 by siRNAs resulted in decreased
IFITM3 mRNA levels (Fig. 4C) and promoter activity in re-
porter assays (Fig. 4D), thereby clearly showing the involve-
ment of TEF-1 in IFITM3 gene regulation.
In addition to the sequences between 155 and 149
(Fig. 3D, site A) in the IFITM3 promoter, TEF-1 also exhibits
a weak binding to a secondary site, 5 0-AGTAATT-3 0 (Fig. 3D,
site B) between positions 170 and 164, which varies from
the canonical M-CAT motif in the ﬁrst and ﬁfth positions. A
systematic study to identify nucleotides in the M-CAT motif,
most important for the activation of the c-TNT promoter in
the chick embryo primary muscle cells has shown that a shift
in the ﬁfth position of the TEF-1 binding site 5 0-CATTCCT-
3 0 from C to A resulted in a signiﬁcant decrease in the pro-
moter activity [21]. This could explain the weaker binding of
TEF-1 to site B and stronger binding to site A (Fig. 3E). How-
ever, even though the majority of the activation potential
seems to arise from site A, site B also contributes to the activity
of the IFITM3 promoter as its mutation resulted in a modest
396 S. Cuddapah et al. / FEBS Letters 582 (2008) 391–397decrease in BRGl-mediated activation (Fig. 1A, mutants A
and B). Both the TEF-1 binding sites A and B are completely
conserved between IFITM3, IFITM2 and IFITM1 [7], suggest-
ing a similar mechanism in the regulation of all the IFITM
genes.
Several cofactors that are required for TEF-1 activity have
been identiﬁed [13,22,23]. TONDU, the mammalian homolog
of Drosophila vestigial gene, binds to all the four TEAD
proteins [24]. YAP65, that interacts with all the four TEAD
proteins has been shown to be a general transcriptional
co-activator in mammalian cells [15]. TAZ also has been
shown to be a co-activator of TEF-1 [13]. This study showed
that TEF-1 and the BAF complex cooperatively activate the
IFITM3 gene, which suggests that the BAF complex could
be a co-activator of TEF-1 during the regulation of IFITM3.
In this study, we found that TEF-1 knock-down resulted in
an increase in the basal expression levels of the IFITM3 gene in
SW-13 cells, suggesting that TEF-1 could play a repressive role
in the absence of the co-activating BAF complex. TEF-1 has
been suggested to act as a repressor of the a-tropomyosin
transgene in the early embryo. The lack of the co-repressors
or the presence of co-activators has been speculated as the
reason for the loss of repressive activity of TEF-1 during the
later stages of development [25]. Over-expression of TEF-1
resulting in the repression activity of TEF-1 is also well known.
It has been suggested that this phenomenon could be due to
squelching, where the co-activator could be titrated out by
the binding of the over-expressed TEF-1 [15,26–28]. Thus,
the repressive eﬀect of TEF-1 could be due to a co-repressor
activity, which may be recruited by TEF-1 in the absence of
the co-activator, the BAF complex being such a co-activator
in our studies.
We previously found the involvement of Spl in the BRG1
mediated activation of the IFITM3 gene. In this study, we have
identiﬁed a novel player, TEF-1 in its regulation. Our data
indicate that the expression of the IFITM genes is regulated
by multiple transcription factors through interaction with the
chromatin remodeling complexes and suggests a role for
TEF-1 in the IFN signaling pathway.
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